Shuttle Pharmaceuticals Holdings (SHPH) Research & Development (2021 - 2026)

Shuttle Pharmaceuticals Holdings' Research & Development history runs 6 years deep, the most recent figure standing at $267240.0 for Q1 2026.

• On a quarterly basis, Research & Development fell 83.02% year-over-year to $267240.0 in Q1 2026; TTM through Mar 2026 was $2.7 million, a 40.18% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, up 12.05% from the prior year.
• Research & Development retreated to $267240.0 in Q1 2026 per SHPH's latest filing, from $554831.0 in the prior quarter.
• Across five years, Research & Development topped out at $1.6 million in Q1 2025 and bottomed at -$1436.0 in Q4 2022.
• The 5-year median for Research & Development is $693356.0 (2023), against an average of $734605.3.
• Across the five-year window, Research & Development tumbled 100.32% in 2022 and surged 48383.84% in 2023, its largest moves.
• Year by year, Research & Development stood at -$1436.0 in 2022, then jumped by 48383.84% to $693356.0 in 2023, then jumped by 46.94% to $1.0 million in 2024, then tumbled by 45.54% to $554831.0 in 2025, then tumbled by 51.83% to $267240.0 in 2026.
• Per Business Quant, the three latest SHPH Research & Development figures stand at $267240.0 (Q1 2026), $554831.0 (Q4 2025), and $900000.0 (Q3 2025).